Efficacy and Safety of Guselkumab, an Anti–interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis | Zendy

Tadashi Terui | Zendy; Satomi Kobayashi | Zendy; Yukari Okubo | Zendy; Masamoto Murakami | Zendy; Keiichiro Hirose | Zendy; Hiroshi Kubo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Guselkumab, an Anti–interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis

Author(s) -

Tadashi Terui,

Satomi Kobayashi,

Yukari Okubo,

Masamoto Murakami,

Keiichiro Hirose,

Hiroshi Kubo

Publication year - 2018

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2017.5937

Subject(s) - medicine , palmoplantar pustulosis , randomized controlled trial , dermatology life quality index , placebo , placebo controlled study , anakinra , gastroenterology , surgery , dermatology , psoriasis , double blind , pathology , disease , alternative medicine

Palmoplantar pustulosis (PPP) is a recalcitrant skin disease with no biologics currently approved for treatment. The involvement of interleukin 23 (IL-23) and cytokines of the type 17 helper T cell lineage in the pathogenesis of PPP has been recently postulated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research